The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlethora Solutions Holdings Plc Regulatory News (PLE)

  • There is currently no data for PLE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Plethora Solutions Holdings Plc

2 Feb 2016 14:52

RNS Number : 8340N
Brewin Dolphin Limited
02 February 2016
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Identity of the person whose positions/dealings are being disclosed:

Brewin Dolphin Limited

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Plethora Solutions Holdings Plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

(e) Date position held/dealing undertaken:

01/02/2016

(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?

YES - Regent Pacific Group Limited

 

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ordinary GBP0.01

 

 

Interests

Short positions

Number

%

Number

%

Relevant securities owned and/or controlled:

8,895,650

1.0805

 

 

(2) Derivatives (other than options):

 

 

 

 

(3) Options and agreements to purchase/sell:

 

 

 

 

 

TOTAL:

8,895,650

 

1.0805

 

 

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

 

Ord GBP0.01

Sale

50,000

2.82p

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

 

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

 

 

 

 

 

 

 

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

Date of disclosure:

02/02/2016

Contact name:

Chris Drewitt

Telephone number:

0191 279 7216

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETTTMITMBAMBBF
Date   Source Headline
17th Nov 20107:00 amRNSChange of Adviser
10th Nov 20102:27 pmRNSHolding in Company
7th Sep 20107:00 amRNSHalf Yearly Report
29th Jul 20102:27 pmRNSHolding(s) in Company
23rd Jul 201010:55 amRNSHolding(s) in Company
19th Jul 20107:00 amRNSNew Product Launch
13th Jul 20107:00 amRNSPre-close Trading Update
30th Jun 20107:00 amRNSTerm Loan Agreement
10th Jun 201012:06 pmRNSLTIP Awards
2nd Jun 20107:00 amRNSAmerican Urological Association Showcase
27th May 20109:27 amRNSResult of AGM
17th May 20107:00 amRNSCommercial Update - The Urology Company
6th May 20107:00 amRNSAnnual Report and Accounts
5th May 20107:00 amRNSIssue of Equity
12th Apr 20107:00 amRNSExclusive Distribution Agreement
9th Mar 20107:00 amRNSPreliminary Results
24th Feb 20103:31 pmRNSHolding(s) in Company
23rd Feb 20107:00 amRNSNotice of Results
19th Jan 20107:00 amRNSPre-Close Trading Update
14th Dec 20095:23 pmRNSHolding(s) in Company
7th Dec 200911:23 amRNSResult of EGM
30th Nov 20097:00 amRNSExclusive License and Distribution Agreement
23rd Nov 20097:00 amRNSExclusive License and Distribution Agreement
19th Nov 20094:23 pmRNSDirector/PDMR Shareholding
18th Nov 20097:23 amRNSPlacing and Convertible Loan Note
30th Sep 20097:00 amRNSClinical Update re: PSD506
17th Sep 20097:00 amRNSInterim Results
7th Aug 20094:42 pmRNSHolding(s) in Company
5th Aug 200910:42 amRNSHolding(s) in Company
29th Jul 20097:00 amRNSFinal Phase III Pivotal Trial Results PSD502
16th Jul 20097:00 amRNSPSD503 Update - Evaluation and Option Agreement
25th Jun 20091:57 pmRNSAGM Statement and Trading Update
15th Jun 20093:57 pmRNSHolding(s) in Company
29th May 20093:34 pmRNSAnnual Report and Accounts and AGM Notice
26th May 20097:05 amRNSDirectorate Change
26th May 20097:00 amRNSGlobal Agreement, Restructuring and Final Results
1st Apr 20097:00 amRNSUpdate re: PSD502
19th Feb 20097:00 amRNSDirectorate Change
18th Feb 20099:24 amRNSClinical Update PSD502
16th Feb 200911:31 amRNSLoan Agreement and US License Amendment
16th Feb 200911:26 amRNSResult of General Meeting
22nd Jan 20097:00 amRNSFunding Update and Notice of GM
23rd Dec 20084:17 pmRNSHolding(s) in Company
18th Dec 200811:55 amRNSHolding(s) in Company
11th Dec 20089:12 amRNSHolding(s) in Company
8th Dec 20087:00 amRNSIssue of Equity
8th Dec 20087:00 amRNSClinical Update: PSD502
14th Nov 20087:00 amRNSHolding(s) in Company
14th Nov 20087:00 amRNSErecAid Study Results
7th Nov 20087:00 amRNSPhase III European Clinical Trial Results PSD502

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.